S&PCORRECT: Dexia's Core Entities Remain On Watch Developing; Awaiting Details Of New Strategy Oct 08

  • ID: 1885591
  • October 2008
  • Standard & Poors
1 of 3

PARIS (Standard & Poor's) Oct. 10, 2008--Standard & Poor's Ratings Services said today that it is maintaining on CreditWatch its 'A+/A-1' long- and short-term counterparty credit ratings on four banks belonging to Belgium-based banking group Dexia S.A., where they were placed on Oct. 7, until it resolves the uncertainties about new management's strategy. Remaining on CreditWatch with developing implications are the group's core entities, Dexia Cr-dit Local (DCL), Dexia Bank S.A. (DB), and Dexia Banque Internationale - Luxembourg (DBIL). Remaining on CreditWatch with negative implications is Italy-based Dexia Crediop SpA. The 'BBB' debt ratings on the group's hybrid capital instruments and junior subordinated remain on CreditWatch with negative implications. The 'AAA' senior secured debt ratings on all covered bonds that...

Companies mentioned in this report are: Dexia Crediop SpA
Action: CreditWatch Update

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Dexia Crediop SpA

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.